BRD3308 (BRD 3308)
- Product Name
- BRD3308 (BRD 3308)
- CAS No.
- 1550053-02-5
- Chemical Name
- BRD3308 (BRD 3308)
- Synonyms
- BRD3308;BRD3308 (BRD 3308);BRD3308 >=98% (HPLC);BRD3308, 10 mM in DMSO;4-Acetamido-N-(2-amino-4-fluorophenyl)benzamide;4-(Acetylamino)-N-(2-amino-4-fluorophenyl)benzamide;Benzamide, 4-(acetylamino)-N-(2-amino-4-fluorophenyl)-;β-cells,glucolipotoxicity,inflammatory,BRD-3308,Human immunodeficiency virus,BRD3308,Histone deacetylases,HDAC3,diabetes,HDAC,HIV-1,Inhibitor,Apoptosis,latency,BRD 3308,cytokines,hyperglycaemia,HIV,inhibit,insulin
- CBNumber
- CB64844594
- Molecular Formula
- C15H14FN3O2
- Formula Weight
- 287.29
- MOL File
- 1550053-02-5.mol
BRD3308 (BRD 3308) Property
- Boiling point:
- 449.9±45.0 °C(Predicted)
- Density
- 1.382±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMSO:57.0(Max Conc. mg/mL);198.41(Max Conc. mM)
- form
- A solid
- pka
- 12.13±0.70(Predicted)
- color
- Off-white to light yellow
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H315Causes skin irritation
H319Causes serious eye irritation
- Precautionary statements
-
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- SML1639
- Product name
- BRD3308
- Purity
- ≥98% (HPLC)
- Packaging
- 5mg
- Price
- $154
- Updated
- 2025/07/31
- Product number
- SML1639
- Product name
- BRD3308
- Purity
- ≥98% (HPLC)
- Packaging
- 25mg
- Price
- $308
- Updated
- 2025/07/31
- Product number
- BB168411
- Product name
- BRD 3308
- Packaging
- 50mg
- Price
- $332.5
- Updated
- 2021/12/16
- Product number
- CS-0015975
- Product name
- BRD3308
- Purity
- 95.94%
- Packaging
- 10mg
- Price
- $160
- Updated
- 2021/12/16
- Product number
- 4572DW
- Product name
- CID72734382
- Packaging
- 10mg
- Price
- $178
- Updated
- 2021/12/16
BRD3308 (BRD 3308) Chemical Properties,Usage,Production
Uses
BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3].
Biological Activity
BRD3308 is a highly selective inhibitor of histone deacetylase 3 (HDAC3) with an IC50 value of 65 nM for HDAC3 vs. IC50 values of 1.08 μM and 1.15 μM for HDAC1 and HDAC2, respectively. BRD3308 protected pancreatic β cells, suppressing inflammatory cytokine-induced apoptosis and increasing insulin release without the toxicity associated with HDAC1 and HDAC2 inhibitors. In a r at model of type 2 diabetes, BRD3308 reduced hyperglycemia and increased insulin secretion without affecting weight gain. In another study, BRD3308 was found to activate HIV-1 transcription, disrupting HIV-1 latency.', 'BRD3308 promotes outgrowth of HIV-1 (human immunodeficiency virus 1) from inactive infected patient cells. It helps to increase β-cell proliferation.
in vivo
BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo[2].
| Animal Model: | Male Zucker Diabetic Fatty (Obese) rats (6-week-old)[2] |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; every second day |
| Result: | Reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes. |
IC 50
HDAC3: 54 nM (IC50); HDAC3: 29 nM (Ki); HDAC1: 1260 nM (IC50); HDAC1: 5100 nM (Ki); HDAC2: 1340 nM (IC50); HDAC2: 6300 nM (Ki); HIV-1
References
[1] Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9(8):e102684. DOI:10.1371/journal.pone.0102684
[2] Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17(7):703-7. DOI:10.1111/dom.12470
[3] Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11(2):363-74. DOI:10.1021/acschembio.5b00640
BRD3308 (BRD 3308) Preparation Products And Raw materials
Raw materials
Preparation Products
BRD3308 (BRD 3308) Suppliers
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- 021-52996696,15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4757
- Advantage
- 55
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 0-2022843681 15618226720
- Fax
- +86-21-51601218
- chaolaichem@foxmail.com
- Country
- China
- ProdList
- 12476
- Advantage
- 58
- Tel
- +86-0576-88813233 +86-13396860566
- sales@pharm-intermediates.com
- Country
- China
- ProdList
- 1991
- Advantage
- 58
- Tel
- 0512-65816829 18662214788
- Fax
- 0512-65816829
- info@rovathin.com.cn
- Country
- China
- ProdList
- 9987
- Advantage
- 58
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-708-310-1919 +1-13798911105
- Fax
- 708-557-7486
- sales@invivochem.cn
- Country
- United States
- ProdList
- 6391
- Advantage
- 58
- Tel
- 86-571-88216897,88216896 13588875226
- Fax
- 86-571-88216895
- sales@hzclap.com
- Country
- CHINA
- ProdList
- 6312
- Advantage
- 58